Biblio
Export 1529 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is K [Clear All Filters]
“18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.”, J Alzheimers Dis, vol. 70, no. 4, pp. 1197-1207, 2019.
, “Anemia in Association with Cognitive Impairment: A Systematic Review and Meta-Analysis.”, J Alzheimers Dis, vol. 72, no. 3, pp. 803-814, 2019.
, “Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer's Disease-Matched Cohort Study.”, J Alzheimers Dis, vol. 68, no. 1, pp. 127-136, 2019.
, “APOE ɛ4 Carriers Show Delayed Recovery of Verbal Memory and Smaller Entorhinal Volume in the First Year After Ischemic Stroke.”, J Alzheimers Dis, vol. 71, no. 1, pp. 245-259, 2019.
, “APOE ɛ4 Carriers Show Delayed Recovery of Verbal Memory and Smaller Entorhinal Volume in the First Year After Ischemic Stroke.”, J Alzheimers Dis, vol. 71, no. 1, pp. 245-259, 2019.
, “The Association between Mushroom Consumption and Mild Cognitive Impairment: A Community-Based Cross-Sectional Study in Singapore.”, J Alzheimers Dis, vol. 68, no. 1, pp. 197-203, 2019.
, “CD14 and Toll-Like Receptor 4 Promote Fibrillar Aβ42 Uptake by Microglia Through A Clathrin-Mediated Pathway.”, J Alzheimers Dis, vol. 68, no. 1, pp. 323-337, 2019.
, “Cerebral Microbleeds Are Associated with Cerebral Hypoperfusion in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 71, no. 1, pp. 273-280, 2019.
, “Cerebral Microbleeds Are Associated with Cerebral Hypoperfusion in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 71, no. 1, pp. 273-280, 2019.
, “The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus.”, J Alzheimers Dis, vol. 68, no. 1, pp. 311-322, 2019.
, “The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus.”, J Alzheimers Dis, vol. 68, no. 1, pp. 311-322, 2019.
, “A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR.”, J Alzheimers Dis, vol. 67, no. 1, pp. 181-195, 2019.
, “Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions.”, J Alzheimers Dis, vol. 71, no. 3, pp. 715-732, 2019.
, “Evaluation of Associations of Alzheimer's Disease Risk Variants that Are Highly Expressed in Microglia with Neuropathological Outcome Measures.”, J Alzheimers Dis, vol. 70, no. 3, pp. 659-666, 2019.
, “Exercise Training in Amnestic Mild Cognitive Impairment: A One-Year Randomized Controlled Trial.”, J Alzheimers Dis, vol. 71, no. 2, pp. 421-433, 2019.
, “A Fragment of S38AA is a Novel Plasma Biomarker of Alzheimer's Disease.”, J Alzheimers Dis, vol. 71, no. 4, pp. 1163-1174, 2019.
, “Gender and Educational Differences in the Association between Lifestyle and Cognitive Decline over 10 Years: The Doetinchem Cohort Study.”, J Alzheimers Dis, vol. 70, no. s1, pp. S31-S41, 2019.
, “Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment.”, J Alzheimers Dis, vol. 67, no. 2, pp. 481-488, 2019.
, “Identifying Unmet Needs of Family Dementia Caregivers: Results of the Baseline Assessment of a Cluster-Randomized Controlled Intervention Trial.”, J Alzheimers Dis, vol. 67, no. 2, pp. 527-539, 2019.
, “Identifying Unmet Needs of Family Dementia Caregivers: Results of the Baseline Assessment of a Cluster-Randomized Controlled Intervention Trial.”, J Alzheimers Dis, vol. 67, no. 2, pp. 527-539, 2019.
, “Identifying Unmet Needs of Family Dementia Caregivers: Results of the Baseline Assessment of a Cluster-Randomized Controlled Intervention Trial.”, J Alzheimers Dis, vol. 67, no. 2, pp. 527-539, 2019.
, “Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.”, J Alzheimers Dis, vol. 67, no. 2, pp. 639-651, 2019.
, “Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.”, J Alzheimers Dis, vol. 67, no. 2, pp. 639-651, 2019.
, “Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.”, J Alzheimers Dis, vol. 67, no. 2, pp. 639-651, 2019.
, “Inferring the Molecular Mechanisms of Noncoding Alzheimer's Disease-Associated Genetic Variants.”, J Alzheimers Dis, vol. 72, no. 1, pp. 301-318, 2019.
,